Review article: Oesophageal disorders in chronic liver disease

被引:2
|
作者
Idalsoaga, Francisco [1 ]
Diaz, Luis Antonio [1 ]
Ayares, Gustavo [1 ]
Cabrera, Daniel [2 ,3 ]
Chahuan, Javier [1 ]
Monrroy, Hugo [1 ]
Halawi, Houssam [4 ]
Arrese, Marco [1 ]
Arab, Juan Pablo [1 ,5 ]
机构
[1] Pontificia Univ Catolica Chile, Escuela Med, Dept Gastroenterol, Santiago, Chile
[2] Univ los Andes, Fac Med, Santiago, Chile
[3] Univ Bernardo O Higgins, Escuela Med, Fac Ciencias Med, Ctr Estudios Invest Salud & Soc, Santiago, Chile
[4] Mayo Clin, Div Gastroenterol & Hepatol, Rochester, MN USA
[5] Virginia Commonwealth Univ, Sch Med, Div Gastroenterol Hepatol & Nutr, Dept Internal Med, Richmond, VA USA
关键词
GASTROESOPHAGEAL-REFLUX DISEASE; PROTON PUMP INHIBITORS; DYSPLASTIC BARRETTS-ESOPHAGUS; ENDOSCOPIC VARICEAL LIGATION; CIRRHOTIC-PATIENTS; RISK-FACTORS; LIFE-STYLE; PORTAL-HYPERTENSION; ADVERSE EVENTS; FOLLOW-UP;
D O I
10.1111/apt.18193
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Oesophageal disorders and chronic liver disease are common worldwide and significantly impact quality of life. The intricate link between these conditions, including how oesophageal disorders like GERD, Barrett's oesophagus and oesophageal cancer affect and are affected by chronic liver disease, remains poorly understood. Aims: To review the relationship between oesophageal disorders and chronic liver disease, evaluating epidemiology, pathophysiology and therapeutic factors. Methods: We reviewed the literature on the relationship between oesophageal disorders and chronic liver disease, including cirrhosis, using the PubMed database Results: Oesophageal disorders such as gastroesophageal reflux disease, Barrett's oesophagus, oesophageal cancer, oesophageal motor disorders and oesophageal candidiasis are prevalent among individuals with cirrhosis, exacerbating the burden of liver disease. These diseases have a multifaceted symptomatology and pathogenic basis, posing a significant challenge in cirrhotic patients that necessitates careful diagnosis and management. Additionally, therapies frequently used for these diseases, such as proton pump inhibitors, require careful consideration in cirrhotic patients due to potential adverse effects and altered pharmacokinetics. Managing oesophageal disorders in cirrhotic patients requires a cautious approach due to possible interactions with medications and the risk of adverse effects. Furthermore, symptoms associated with these conditions are often exacerbated by common interventions in patients with cirrhosis, such as band ligation for oesophageal varices. Conclusions: Oesophageal disorders are common in cirrhosis and increase the disease burden. These conditions require careful management due to complex symptoms and treatment risks. Proton pump inhibitors and other therapies must be used cautiously, as cirrhosis interventions can worsen symptoms.
引用
收藏
页码:715 / 726
页数:12
相关论文
共 50 条
  • [1] Review article: coagulation disorders in chronic liver disease
    Peck-Radosavljevic, M.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2007, 26 : 21 - 28
  • [2] Review article: chronic liver disease and pregnancy
    Faulkes, Rosemary E.
    Chauhan, Abhishek
    Knox, Ellen
    Johnston, Tracey
    Thompson, Fiona
    Ferguson, James
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2020, 52 (03) : 420 - 429
  • [3] Review article: thrombocytopenia in chronic liver disease
    Poordad, F.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2007, 26 : 5 - 11
  • [4] Review article: gastro-oesophageal reflux disease in asthma and chronic obstructive pulmonary disease
    Broers, C.
    Tack, J.
    Pauwels, A.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2018, 47 (02) : 176 - 191
  • [5] Review article: a pharmacoeconomic analysis of thrombocytopenia in chronic liver disease
    Brown, R. S., Jr.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2007, 26 : 41 - 48
  • [6] Letter: Potential impact of Helicobacter pylori infection on oesophageal disorders in chronic liver disease
    Kountouras, Jannis
    Vardaka, Elisabeth
    Zavos, Christos
    Chatzopoulos, Dimitrios
    Tzitiridou-Chatzopoulou, Maria
    Tzilves, Dimitrios
    Zournatzidou, Georgia
    Kyrailidou, Foteini
    Mouratidou, Maria C.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2024, 60 (08) : 1139 - 1140
  • [7] Review article: the pathophysiology of gastro-oesophageal reflux disease - oesophageal manifestations
    Castell, DO
    Murray, JA
    Tutuian, R
    Orlando, RC
    Arnold, R
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2004, 20 : 14 - 25
  • [8] Review article: the nature of oesophageal injury in gastro-oesophageal reflux disease
    De Hertogh, G.
    Ectors, N.
    Van Eyken, P.
    Geboes, K.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2006, 24 : 17 - 26
  • [9] Review article: thrombocytopenia in chronic liver disease and pharmacologic treatment options
    Giannini, EG
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2006, 23 (08) : 1055 - 1065
  • [10] Review article: depression and the use of antidepressants in patients with chronic liver disease or liver transplantation
    Mullish, B. H.
    Kabir, M. S.
    Thursz, M. R.
    Dhar, A.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2014, 40 (08) : 880 - 892